Increased risk of serious vasoconstrictive adverse effects, including coronary vasospasm and myocardial infarction.
Do not administer sumatriptan and ergotamine within 24 hours of each other.
Source: KDT 7e · p179
Triptan · Headache management
Sumatriptan is a 5HT1-receptor agonist. It is the 5HT1-receptor agonist of choice for acute migraine treatment based on its clinical efficacy and safety profile.
Avoid unless potential benefit outweighs risk.
Not recommended during nursing
Increased risk of serious vasoconstrictive adverse effects, including coronary vasospasm and myocardial infarction.
Do not administer sumatriptan and ergotamine within 24 hours of each other.
Source: KDT 7e · p179
Increased risk of adverse effects from sumatriptan, including serotonin syndrome.
Sumatriptan is contraindicated in patients who have taken an MAO inhibitor within the preceding 2 weeks.
Source: G&G 14e · p293, p302
Increased risk of adverse effects from sumatriptan, including serotonin syndrome.
Sumatriptan is contraindicated in patients who have taken an MAO inhibitor within the preceding 2 weeks.
Source: G&G 14e · p293, p302
Drug interaction classified as: synergy.
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy.
Source: DDInter
.
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e, BNF·Verified: 2026-05-13 · House clinical team